

Clinical Validation report of Novel Coronavirus (SARS-Cov-2) Antigen Rapid Test device (saliva)

Product name: Novel Coronavirus (SARS-Cov-2) Antigen Rapid
Test device (saliva)

Package Specification: 20 tests/kit

Manufacturer: Hangzhou Realy Tech Co., Ltd

I. Clinical validation time

This clinical evaluation was conducted from October 2020 to November, 2020.

II. Background information for clinical evaluation

Since December 2019, world has successively discovered multiple cases of patients with new-type coronavirus pneumonia. With the spread of the epidemic, China and abroad have also been found. As an acute respiratory infectious disease, the disease has been included in the Class B infectious diseases stipulated in the Law of the People's Republic of China on the Prevention and Control of Infectious Diseases, and is managed as a Class A infectious disease. Based on the current epidemiological investigation, the incubation period is 1-14 days, mostly 3-7 days.

The main manifestations are fever, dry cough, and fatigue. A few patients have symptoms such as nasal congestion, runny nose, sore throat, myalgia and diarrhea. Severe patients usually have dyspnea and / or hypoxemia one week after the onset of symptoms, and severe patients can quickly progress to acute respiratory distress syndrome, septic shock, difficult to correct metabolic acidosis, coagulation dysfunction and multiple organ Functional failure, etc. It is worth noting that in the course of severe and critically ill patients, there may be moderate to low fever, even without obvious fever.

Mild patients showed only low fever, mild fatigue, and no pneumonia. Judging from the current cases, most patients have a good prognosis, and a few patients are critically ill. The elderly and those with chronic underlying disease have a better prognosis. Symptoms in children are relatively mild.

The Novel Coronavirus (SARS-Cov-2) Antigen Rapid Test device (saliva) developed by our company can help diagnose whether patients are infected with the Novel Coronavirus. It has further enriched the detection methods of Novel Coronavirus, expanded the supply of detection reagents, and fully served the needs of epidemic prevention and control.

III. Test purposes

The Novel Coronavirus (SARS-Cov-2) Antigen Rapid Test device (saliva) produced by Hangzhou Realy Technology Co., Ltd. was used to verify the feasibility of clinical evaluation and the reliability of test results for Chinese subjects.

The purpose of research of the clinical test is to calculate the consistency percentage of negative/positive and the total consistency percentage and Kappa coefficient by statistically analyzing test results through comparative experimental research.

IV. Test design

1. Test plan selection and reasons

In vitro diagnostic reagents for testing and reference reagents were used to conduct comparative research tests on clinically suspected Novel Coronavirus saliva samples, and it was proved that the in vitro diagnostic reagents used in the test can achieve the expected assistance in infection of the Novel Coronavirus.

2. Sample volume required

The total number of clinical trials of this product is not less than 100 cases. The samples is classified into the positive group and the negative group as per the test results of the reference product. Meanwhile, the (unfrozen) nasopharyngeal swab samples shall be tested via the RT-PCR from the same patient at same time, then the saliva sample test results of the product tested and the

nasopharyngeal swab sample RT-PCR test results shall be compared, with statistical analysis being made.

3. Sample inclusion/exclusion certification.

The positive group and negative group in this experiment are applicable to the following inclusion/exclusion criteria.

Positive group inclusion:

PCR Test is positive;
symptoms are clinically positive;

Negative inclusion:

PCR test is negative;

Sample collection, processing

It is applicable to the diagnosis of the Novel coronavirus from the samples of saliva. Use freshly collected samples for optimal test performance. Inadequate sample collection or improper sample handling may yield a false-negative result.

Sample collection procedure: The oral fluid specimen should be collected using the saliva collect cup provided with the kit. Follow the detailed Directions for Use refer to product IFU. No other collection cup should be used with this assay. Oral fluid collected at any time of the day may be used. **NOTE: Do not place anything in the mouth including food, drink, gum, tobacco, water and mouthwash products for at least 10 minutes prior to collection of oral fluid specimen.**

Specimen preparation:

When the saliva is collected, follow the direction to prepare the specimen with buffer provided with the kit.

4. In vitro diagnostic reagents and reference products for testing

5.1 Test in vitro diagnostic reagents

Name: Novel Coronavirus (SARS-Cov-2) Antigen Rapid Test device (saliva)

Specification: 20 tests/kit

LOT: 202010001

Expiry: October, 2022 (Tentative)

Storage Conditions: Store in a dry place at 2-30°C, protected from light. After opening the inner package, the test card will become invalid due to moisture absorption. Please use it within 1 hour.

Source: Hangzhou Realy Tech Co., Ltd

5.2 Reference products

Name: Novel Coronavirus (2019-nCoV) Nucleic Acid Diagnostic Kit (PCR-Fluorescence Probing)

Manufacturer: Sansure Biotech Inc.

Storage Conditions: Store in a dry place at 2-8°C, protected from light.

V. Experiment method

Allow the test device, specimen, extraction buffer to equilibrate to room temperature (15-30°C) prior to testing. Do not place anything in the mouth including food, drink, gum, tobacco, water and mouthwash products for at least 10 minutes prior to collection of oral fluid specimen.

1. Spit enough saliva into the saliva collect cup/bag.

2. Draw the saliva from the cup with a dropper, transfer 4 drops of saliva to the extraction tube.
 3. Take out an extraction tube and a bottle of extraction buffer, remove the extraction buffer bottle cap, add all the extraction buffer into the extraction tube.
 4. Take out a nozzle and close into the extraction tube, gently shake the extraction tube vertically for about 5 seconds to allow saliva mix well with extraction buffer.
 5. Fold the used cup/bag in half and discard it into the plastic bag as medical waste in accordance with local regulations
- Note: The detection steps need to be completed under protection against infection.

VI. Statistical methods of statistical analysis of clinical research data

A Methods evaluating clinical performance

Whether various indexes can reach the standards of clinical evaluation shall be judged by calculating the consistency percentage of negative/positive and the total consistency percentage in the test results of the product tested and the reference product, to validate the accuracy and applicability of the product in clinical applications. The product tested shall be subject to tests through the sample of different types, with statistics on the results. Meanwhile, different types of sample of the subjects shall be subject to determination by the product tested synchronously, and then the determination results of both shall be compared. The test results recorded shall be subject to statistical analysis upon completion of determination of all clinical samples, to calculate the consistency percentage of negative/positive and the total consistency percentage. Afterwards, equivalence of both shall be evaluated as per these statistical indexes

B Statistical method

The products launched on the market shall be subject to comparative study and evaluation. Kappa inspection: each sample shall be tested with the product tested and the reference product respectively, and then the consistency in statistical results of these two inspection methods shall be compared through Kappa inspection.

The data shall be subject to Kappa inspection and analysis and the Kappa coefficient shall be calculated. Favorable consistency can be proven if Kappa is > 0.8 . The consistency in test results of the product tested and the reference product is evaluated as per the evaluation standards.

VII Standards of clinical evaluation

The coincidence rate shall be calculated by comparing with the reference product whose marketing is approved. The product performance shall meet the following requirements.

- 1) Coincidence rate of negative: the sample whose test results are negative for both the product tested and the reference product and the proportion in the sample whose test results are negative for the reference product shall be more than 95%.
- 2) Coincidence rate of positive: the sample whose test results are positive for both the product tested and the reference product and the proportion in the sample whose test results are positive for the reference product shall be more than 85%.
- 3) Total coincidence rate: the sample whose test results are the same for the product tested and the

reference product and its proportion in the total number of samples shall be more than 90%.

Method		2019-nCoV nucleic acid test kit (RT-PCR)		Total Results
The Novel Coronavirus (SARS-Cov-2) Antigen Rapid Test device (saliva)	Result	positive	negative	
	positive	A	B	A+B
	negative	C	D	C+D
Total Results		A+C	B+D	A+B+C+D

Clinical sensitivity = $A/(A+C)*100\%$

Clinical specificity = $D/(B+D)*100\%$

Accuracy: $(A+D)/(A+B+C+D)*100\%$

If the coincidence rate of positive/negative can meet clinical requirements, two methods or Products are considered as equivalent; If the coincidence rate of positive/negative is greatly different, the clinical scheme should be re-designed.

4)Kappa consistency analysis shall be adopted for statistical analysis of reference reagents.

The results of the product tested are statistical materials and can be per the table below:

Method		2019-nCoV nucleic acid test kit (RT-PCR)		Total Results
The Novel Coronavirus (SARS- Cov-2) Antigen Rapid Test device (saliva)	Result	positive	negative	
	positive	A	B	A+B
	negative	C	D	C+D
Total Results		A+C	B+D	A+B+C+D

$P_0 = (A+D)/(A+B+C+D)*100\%$

$P_e = ((A+B)(A+C) + (A+B)(B+D)) / (A+B+C+D)^2$

Kappa: $(P_0 - P_e)/(1 - P_e)$

If conducting Kappa consistency analysis for the base data above, high consistency can be judged if the Kappa coefficient is >0.8 , and both systems are considered as equivalent. Consistency is considered if $0.4 < \text{Kappa coefficient} < 0.8$, and the coincidence rate of positive/negative shall be compared, with statistical analysis being made. Two such systems are considered as inconsistent and in-equivalent if the Kappa coefficient is <0.4 .

VIII Provisions for amendments to clinical validation

In general, the clinical validation should not be changed. Any modification to the project during the test should be explained, and the time, reason, process of change, and whether there is a record of the change are explained in detail and its impact on the evaluation of the entire research result is explained.

IX. Results and Analysis of Clinical Tests

In total, 405 patients' samples are included for the unit, all the saliva samples and nasopharyngeal swab samples are tested. Statistics on rapid test results and those of the RT-PCR tested are as follows:

Method		2019-nCoV Nucleic Acid Test Kit (RT-PCR)		Total Results
		Positive	Negative	
The Novel Coronavirus (SARS-Cov-2) Antigen Rapid Test device (saliva)	Results			
	Positive	157	1	158
	Negative	12	235	247
Total Results		169	236	405

Clinical sensitivity = $157/169 = 92.9\%$ (95%CI*:87.89% to 96.00%)

Clinical specificity = $235/236 = 99.58\%$ (95%CI*:97.39% to >99.99%)

Accuracy: $(157+235)/(157+1+12+235) * 100\% = 96.79\%$ (95%CI* 94.53% to 98.17%)

$P_e = (158*169+158*236)/(405*405) = 0.39$

Kappa: $(P_0 - P_e)/(1 - P_e) = 0.95$

*:95% confidence interval

According to the above table, 235 are proven negative of 236 negative specimens, 157 are proven positive of 169 positive specimens. The sensitivity and accuracy are more than 90%, indicating favorable consistency with the reference product. The Kappa=0.95>0.8, indicating favorable and high consistency of two methods and equivalence of two such systems.

X Analysis on Inconsistency in Test Results

NO.	Age	Gender	Rapid Test	RT-PCR	Clinical diagnostic
5	21	F	Negative	Positive (RdRP gene)	Infection 6 days
14	39	F	Negative	Positive (N gene)	Infection 6 days
25	43	F	Negative	Positive (N gene)	Infection 7 days
37	36	M	Negative	Positive (N gene)	Infection 6 days
49	30	M	Negative	Positive (RdRP gene)	Infection 6 days
66	58	F	Negative	Positive (N gene)	Infection 7 days
78	43	F	Negative	Positive (N gene)	Infection 7 days
96	55	M	Negative	Positive (N gene)	Infection 7 days
125	49	F	Negative	Positive (N gene)	Infection 6 days
134	36	F	Negative	Positive (RdRP gene)	Infection 7 days
144	22	M	Negative	Positive (N gene)	Infection 6 days
163	68	M	Negative	Positive (N gene)	Infection 7 days
284	32	M	Positive	Negative(Ct/Cq) >40	Infection 7 days

XI Discussion and Conclusions

1. discussion

A Results of comparative analysis of the product tested and the reference product:

Test results of saliva specimen tested and the reference result: both the coincidence rate of negative/positive and the total coincidence rate are larger than 85%, indicating favorable consistency with the reference product. In the analysis results of Kappa inspection, Kappa was proven >0.8, indicating favorable and high consistency of both methods. Both systems were proven equivalent.

2. Test conclusions

By analyzing the test results of the product tested and the reference product, the consistency percentage of negative/positive and the total consistency percentage are proven high. Moreover, according to the results of statistical analysis, there is no remarkable difference in test results of both, indicating favorable consistency in diagnosis and equivalence of two such systems and can be used for auxiliary diagnosis of those suffering from pneumonia triggered by COVID-19.

X. Quality control methods

On-site quality control

1) During the course of this study, clinical implementors appointed clinical inspectors to conduct regular on-site supervision visits to the research hospital. Through monitoring visits, it was found that all the contents of the research plan were strictly observed, and the correctness of the research data was also guaranteed. Participating researchers have undergone unified training, unified recording methods and judgment standards. The entire clinical trial process is conducted under strict operation, and the test content is complete and authentic. All observations and findings in the clinical trials have been verified and the data are reliable. The conclusions in the clinical trials are derived from the original data.

2) Quality control of clinical experiment process

During the evaluation, quality control was performed daily to ensure that the product was under control. Strict quality control is performed for each trial to ensure the quality of clinical trials.

XI. Prediction of adverse events

Because the Novel Coronavirus (SARS-Cov-2) Antigen Rapid Test device (saliva) is an in vitro diagnostic reagent product, no direct contact with patients is required in clinical trials, no test report is provided to patients, and the test results are only used for comparative studies. It involves personal privacy, does not serve as a basis for auxiliary diagnosis, does not bring any risk to the subject, and does not cause adverse events.

Annex I :Package Insert

Novel Coronavirus (SARS-Cov-2) Antigen Rapid Test Device (saliva)

ANTIGENS IN HUMAN SALIVA

For professional in vitro diagnostic use only.

INTENDED USE

The Novel Coronavirus (SARS-Cov-2) Antigen Rapid Test Device (saliva) is an in vitro diagnostic test for the qualitative detection of novel coronavirus antigens in human saliva, using the rapid immunochromatographic method. The identification is based on the monoclonal antibodies specific for the novel coronavirus antigen. It will provide information for clinical doctors to prescribe correct medications.

SUMMARY

The novel coronavirus belonging to the β genus COVID-19 is an acute respiratory infectious disease. People are generally susceptible. Currently, the patients infected by the novel coronavirus are the main source of infection; asymptomatic infected people can also be an infectious source. Based on the current epidemiological investigation, the incubation period is 1 to 14 days, mostly 3 to 7 days. The main manifestations include fever, fatigue and dry cough. Nasal congestion, runny nose, sore throat, myalgia and diarrhea are found in a few cases.

PRINCIPLE

The Novel Coronavirus (SARS-Cov-2) Antigen Rapid Test Device (saliva) is an immunochromatographic membrane assay that uses highly sensitive monoclonal antibodies to Novel coronavirus.

The test strip is composed of the following three parts, namely sample pad, reagent pad and reaction membrane. The reagent membrane contains the colloidal-gold conjugated with the monoclonal antibodies against Novel coronavirus; the reaction membrane contains the secondary antibodies for Novel coronavirus, and the polyclonal antibodies against the mouse globulin, which are pre-immobilized on the membrane.

When the test device was inserted into saliva sample, conjugates dried in the reagent pad are dissolved and migrate along with the sample. If Novel coronavirus is present in the sample, a complex formed between the anti-Novel coronavirus conjugate and the virus will be caught by the specific anti-Novel coronavirus monoclonal coated on the T region.

Whether the sample contains the virus or not, the solution continues to migrate to encounter another reagent (an anti-mouse IgG antibody) that binds the remaining conjugates, thereby producing a red line on the region C.

The Novel Coronavirus (SARS-Cov-2) Antigen Rapid Test Device (saliva) product can detect SARS-Cov-2 nucleoprotein (mainly) and spike protein.

More than 90% antibody used in Novel Coronavirus (SARS-Cov-2) Antigen Rapid Test Device (saliva) is anti-nucleoprotein of SARS-Cov-2 and target protein is SARS-Cov-2 nucleoprotein. The reagent antibody used in Novel Coronavirus (SARS-Cov-2) Antigen Rapid Test Device (saliva) is anti-Spike protein and target protein is SARS-Cov-2 Consistent fragment of Spike protein.

At present, whether the N501Y in the United Kingdom or the 501Y.V2 in South Africa, the variant fragments are mainly the RBD fragment of the S protein, and the target fragments of the antibodies used in Novel Coronavirus (SARS-Cov-2) Antigen Rapid Test Device (saliva) have not been mutated. So the Novel Coronavirus (SARS-Cov-2) Antigen Rapid Test Device (saliva) can reliably detect the SARS-Cov-2 variants.

So, the Novel Coronavirus (SARS-Cov-2) Antigen Rapid Test Device (saliva) can reliably detect the nucleoprotein and spike protein of genetic SARS-Cov-2 variants.

REAGENTS

The reagent membrane contains the colloidal-gold conjugated with the monoclonal antibodies against Novel coronavirus; the reaction membrane contains the secondary antibodies for Novel coronavirus and the polyclonal antibodies against the mouse globulin which are pre-immobilized on the membrane.

PRECAUTIONS

- For in vitro diagnostic use only.
- Do not use after the expiration date.
- Ensure foil pouch containing test device is not damaged before opening for use.
- Perform test at room temperature 15 to 30°C.
- Wear gloves when handling the samples. Avoid touching the reagent membrane and sample window.
- All samples and used accessories should be treated as infectious and discarded according to local regulations.
- Avoid using bloody samples.

STORAGE AND STABILITY

Store This Novel Coronavirus (SARS-Cov-2) Antigen Rapid Test Device (saliva) at room temperature or refrigerated (2-30°C). Do not freeze. All reagents are stable until the expiration dates marked on their outer packaging and buffer vial.

SPECIMEN COLLECTION AND PREPARATION

- Specimen collection:**
The oral fluid specimen should be collected using the collection tools provided with the kit. Follow the detailed Directions for Use below. No other collection tools should be used with this assay. Oral fluid collected at any time of the day may be used.
- Specimen preparation:**
When the saliva is collected, follow the direction to prepare the specimen with buffer provided with the kit.

MATERIALS		
Materials provided		
• Test device	• Dropper	• Extraction buffer
• Package Insert	• Nozzle	• Extraction tube
• Tube stand	• Saliva collected cup/bag	• Plastic bag

*The 20-test package contains the tube stand, the 1-test and 5-test package use the test box itself as tube stand.

Materials required but not provided

- Timer


DIRECTIONS FOR USE

Allow the test device, specimen, extraction buffer to equilibrate to room temperature (15-30°C) prior to testing. Do not place anything in the mouth including food, drink, gum, tobacco, water and mouthwash products for at least 10 minutes prior to collection of oral fluid specimen.

1. Spit enough saliva into the saliva collect cup/bag.
2. Draw the saliva from the cup with a dropper, transfer 4 drops of saliva to the extraction tube.
3. Take out an extraction tube and a bottle of extraction buffer, remove the extraction buffer bottle cap, add all the extraction buffer into the extraction tube.
4. Take out a nozzle and close into the extraction tube, gently shake the extraction tube vertically for about 5 seconds to allow saliva mix well with extraction buffer.
5. Fold the used cup/bag in half and discard it into the plastic bag as medical waste in accordance with local regulations.



6. Remove the test device from the sealed foil pouch and use it as soon as possible. Best results will be obtained if the assay is performed immediately after opening the foil pouch. Put the test device on a clean and flat surface.
7. Transfer 3 drops of sample into the sample well of test device vertically. Start the timer.
8. Read the result at 10-20 minutes. Don't interpret the result after 20 minutes.



INTERPRETATION OF RESULTS

(Please refer to the illustration above)

POSITIVE: Two red lines appear. One red line appears in the control region (C), and one red line in the test region (T). The shade of color may vary, but it should be considered positive whenever there is even a faint line.

NEGATIVE: Only one red line appears in the control region (C), and no line in the test region (T). The negative result indicates that there are no novel coronavirus particles in the sample or the number of viral particles is below the detectable range.

INVALID: No red line appears in the control region (C). The test is invalid even if there is a line on test region (T). Insufficient sample volume or incorrect procedural techniques are the most likely reasons for control line failure. Review the test procedure and repeat the test using a new test device. If the problem persists, discontinue using the test kit immediately and contact your local distributor.

LIMITATIONS

- The Novel Coronavirus (SARS-Cov-2) Antigen Rapid Test device (saliva) is an acute-phase screening test for qualitative detection. Sample collected may contain antigen concentration below the reagent's sensitivity threshold, so a negative test result does not exclude infection with novel coronavirus.
- The Novel Coronavirus (SARS-Cov-2) Antigen Rapid Test device (saliva) detects viable and non-viable novel coronavirus antigen. Test performance depends on antigen load in the sample and may not correlate with cell culture performed on the same sample. A positive test does not rule out the possibility that other pathogens may be present, therefore, the results must be compared with all other available clinical and laboratory information to make an accurate diagnosis.

- A negative test result may occur if the level of extracted antigen in a specimen is below the sensitivity of the test or if poor quality specimen is obtained.
- Performance of the test has not been established for monitoring antiviral treatment of novel coronavirus.
- Positive test results do not rule out co-infections with other pathogens.
- Negative test results are not intended to rule in other coronavirus infection except the SARS-Cov-2.
- Children tend to shed virus for longer periods of time than adults, which may result in differences in sensitivity between adults and children.
- The concentration of virus in saliva is greatly affected by factors such as meals, diet, smoking, breath fresheners, etc. Therefore, please strictly follow this manual before collecting samples.
- A negative result may occur if the concentration of antigen in a specimen is below the detection limit of the test or if the specimen was collected or transported improperly, therefore a negative test result does not eliminate the possibility of SARS-Cov-2 infection, and should be confirmed by viral culture or PCR.

PERFORMANCE CHARACTERISTICS

Clinical Evaluation

Clinical evaluation was performed to compare the results obtained by Novel Coronavirus (SARS-Cov-2) Antigen Rapid Test device (saliva) and PCR. The results were summarized below:

Method		2019-nCoV Nucleic Acid Test Kit (RT-PCR)		Total Results
The Novel Coronavirus (SARS-Cov-2) Antigen Rapid Test Device (saliva)	Positive	157	1	158
	Negative	12	235	247
	Total Results	169	236	405

Clinical sensitivity = $157/169 = 92.9\%$ (95%CI: 87.89% to 96.00%)
Clinical specificity = $235/236 = 99.58\%$ (95%CI: 97.39% to 99.99%)
Accuracy = $(157 \times 235) / (157 + 12 + 235) = 96.73\%$ (95%CI: 94.53% to 98.17%)

*Confidence Interval

2019-nCoV Strain Tested		Realy Tech product	
Stock 2019-nCoV Concentration		1.1 x 10 ⁷ TCID ₅₀ /mL	
1100	1000	1400	100
1100	1000	2.5 x 10 ⁶	100
1100	1000	1.0 x 10 ⁶	100
1100	1000	1.0 x 10 ⁵	100
1100	1000	1.0 x 10 ⁴	100
1100	1000	1.0 x 10 ³	100
1100	1000	1.0 x 10 ²	100
1100	1000	1.0 x 10 ¹	100
1100	1000	1.0 x 10 ⁰	100
1100	1000	1.0 x 10 ⁻¹	100
1100	1000	1.0 x 10 ⁻²	100
1100	1000	1.0 x 10 ⁻³	100
1100	1000	1.0 x 10 ⁻⁴	100
1100	1000	1.0 x 10 ⁻⁵	100
1100	1000	1.0 x 10 ⁻⁶	100
1100	1000	1.0 x 10 ⁻⁷	100
1100	1000	1.0 x 10 ⁻⁸	100
1100	1000	1.0 x 10 ⁻⁹	100
1100	1000	1.0 x 10 ⁻¹⁰	100
1100	1000	1.0 x 10 ⁻¹¹	100
1100	1000	1.0 x 10 ⁻¹²	100
1100	1000	1.0 x 10 ⁻¹³	100
1100	1000	1.0 x 10 ⁻¹⁴	100
1100	1000	1.0 x 10 ⁻¹⁵	100
1100	1000	1.0 x 10 ⁻¹⁶	100
1100	1000	1.0 x 10 ⁻¹⁷	100
1100	1000	1.0 x 10 ⁻¹⁸	100
1100	1000	1.0 x 10 ⁻¹⁹	100
1100	1000	1.0 x 10 ⁻²⁰	100
1100	1000	1.0 x 10 ⁻²¹	100
1100	1000	1.0 x 10 ⁻²²	100
1100	1000	1.0 x 10 ⁻²³	100
1100	1000	1.0 x 10 ⁻²⁴	100
1100	1000	1.0 x 10 ⁻²⁵	100
1100	1000	1.0 x 10 ⁻²⁶	100
1100	1000	1.0 x 10 ⁻²⁷	100
1100	1000	1.0 x 10 ⁻²⁸	100
1100	1000	1.0 x 10 ⁻²⁹	100
1100	1000	1.0 x 10 ⁻³⁰	100
1100	1000	1.0 x 10 ⁻³¹	100
1100	1000	1.0 x 10 ⁻³²	100
1100	1000	1.0 x 10 ⁻³³	100
1100	1000	1.0 x 10 ⁻³⁴	100
1100	1000	1.0 x 10 ⁻³⁵	100
1100	1000	1.0 x 10 ⁻³⁶	100
1100	1000	1.0 x 10 ⁻³⁷	100
1100	1000	1.0 x 10 ⁻³⁸	100
1100	1000	1.0 x 10 ⁻³⁹	100
1100	1000	1.0 x 10 ⁻⁴⁰	100
1100	1000	1.0 x 10 ⁻⁴¹	100
1100	1000	1.0 x 10 ⁻⁴²	100
1100	1000	1.0 x 10 ⁻⁴³	100
1100	1000	1.0 x 10 ⁻⁴⁴	100
1100	1000	1.0 x 10 ⁻⁴⁵	100
1100	1000	1.0 x 10 ⁻⁴⁶	100
1100	1000	1.0 x 10 ⁻⁴⁷	100
1100	1000	1.0 x 10 ⁻⁴⁸	100
1100	1000	1.0 x 10 ⁻⁴⁹	100
1100	1000	1.0 x 10 ⁻⁵⁰	100
1100	1000	1.0 x 10 ⁻⁵¹	100
1100	1000	1.0 x 10 ⁻⁵²	100
1100	1000	1.0 x 10 ⁻⁵³	100
1100	1000	1.0 x 10 ⁻⁵⁴	100
1100	1000	1.0 x 10 ⁻⁵⁵	100
1100	1000	1.0 x 10 ⁻⁵⁶	100
1100	1000	1.0 x 10 ⁻⁵⁷	100
1100	1000	1.0 x 10 ⁻⁵⁸	100
1100	1000	1.0 x 10 ⁻⁵⁹	100
1100	1000	1.0 x 10 ⁻⁶⁰	100
1100	1000	1.0 x 10 ⁻⁶¹	100
1100	1000	1.0 x 10 ⁻⁶²	100
1100	1000	1.0 x 10 ⁻⁶³	100
1100	1000	1.0 x 10 ⁻⁶⁴	100
1100	1000	1.0 x 10 ⁻⁶⁵	100
1100	1000	1.0 x 10 ⁻⁶⁶	100
1100	1000	1.0 x 10 ⁻⁶⁷	100
1100	1000	1.0 x 10 ⁻⁶⁸	100
1100	1000	1.0 x 10 ⁻⁶⁹	100
1100	1000	1.0 x 10 ⁻⁷⁰	100
1100	1000	1.0 x 10 ⁻⁷¹	100
1100	1000	1.0 x 10 ⁻⁷²	100
1100	1000	1.0 x 10 ⁻⁷³	100
1100	1000	1.0 x 10 ⁻⁷⁴	100
1100	1000	1.0 x 10 ⁻⁷⁵	100
1100	1000	1.0 x 10 ⁻⁷⁶	100
1100	1000	1.0 x 10 ⁻⁷⁷	100
1100	1000	1.0 x 10 ⁻⁷⁸	100
1100	1000	1.0 x 10 ⁻⁷⁹	100
1100	1000	1.0 x 10 ⁻⁸⁰	100
1100	1000	1.0 x 10 ⁻⁸¹	100
1100	1000	1.0 x 10 ⁻⁸²	100
1100	1000	1.0 x 10 ⁻⁸³	100
1100	1000	1.0 x 10 ⁻⁸⁴	100
1100	1000	1.0 x 10 ⁻⁸⁵	100
1100	1000	1.0 x 10 ⁻⁸⁶	100
1100	1000	1.0 x 10 ⁻⁸⁷	100
1100	1000	1.0 x 10 ⁻⁸⁸	100
1100	1000	1.0 x 10 ⁻⁸⁹	100
1100	1000	1.0 x 10 ⁻⁹⁰	100
1100	1000	1.0 x 10 ⁻⁹¹	100
1100	1000	1.0 x 10 ⁻⁹²	100
1100	1000	1.0 x 10 ⁻⁹³	100
1100	1000	1.0 x 10 ⁻⁹⁴	100
1100	1000	1.0 x 10 ⁻⁹⁵	100
1100	1000	1.0 x 10 ⁻⁹⁶	100
1100	1000	1.0 x 10 ⁻⁹⁷	100
1100	1000	1.0 x 10 ⁻⁹⁸	100
1100	1000	1.0 x 10 ⁻⁹⁹	100
1100	1000	1.0 x 10 ⁻¹⁰⁰	100

The test results are below the corresponding concentration of the substances in the table below, which has no effect on the negative and positive test results of the reagent, and there is no cross-reaction.

Virus/Bacteria/Parasite	Strain	Concentration
MERS-coronavirus	N/A	72 µg/mL
	Type 1	1.5 x 10 ⁷ TCID ₅₀ /mL
	Type 3	7.5 x 10 ⁷ TCID ₅₀ /mL
	Type 5	4.5 x 10 ⁷ TCID ₅₀ /mL
	Type 7	1.0 x 10 ⁷ TCID ₅₀ /mL
Adenovirus	Type 8	1.0 x 10 ⁷ TCID ₅₀ /mL
	Type 11	2.5 x 10 ⁷ TCID ₅₀ /mL
	Type 18	2.5 x 10 ⁷ TCID ₅₀ /mL
	Type 23	6.0 x 10 ⁷ TCID ₅₀ /mL
	Type 55	1.5 x 10 ⁷ TCID ₅₀ /mL
Influenza A	H1N1 Denver	3.0 x 10 ⁷ TCID ₅₀ /mL
	H1N1 WIS/33	2.0 x 10 ⁷ TCID ₅₀ /mL
	H1N1 A/Mal/302/54	1.5 x 10 ⁷ TCID ₅₀ /mL
	H1N1 New Caledonia	7.5 x 10 ⁷ TCID ₅₀ /mL
	H3N2 A/Hong Kong/8/58	4.5 x 10 ⁷ TCID ₅₀ /mL
Influenza B	Nevada/03/2011	1.5 x 10 ⁷ TCID ₅₀ /mL
	B/Lee/40	8.5 x 10 ⁷ TCID ₅₀ /mL
	B/Taiwan/29/52	4.0 x 10 ⁷ TCID ₅₀ /mL
	Respiratory syncytial virus	2.5 x 10 ⁷ TCID ₅₀ /mL
	N/A	1 x 10 ⁷ PFU/mL
Legionella pneumophila	Bloomington-2	1 x 10 ⁷ PFU/mL
	Los Angeles-1	1 x 10 ⁷ PFU/mL
	82A3105	1 x 10 ⁷ PFU/mL
	Rhinovirus A16	1.5 x 10 ⁷ TCID ₅₀ /mL
	N/A	1 x 10 ⁷ PFU/mL
Mycobacterium tuberculosis	K	1 x 10 ⁷ PFU/mL
	Erdman	1 x 10 ⁷ PFU/mL
	H37Rv	1 x 10 ⁷ PFU/mL
	CDC1551	1 x 10 ⁷ PFU/mL
	H37Rv	1 x 10 ⁷ PFU/mL
Streptococcus pneumoniae	4752-98 (Mayland 0158-17)	1 x 10 ⁷ PFU/mL
	17B (Poland 23F-16)	1 x 10 ⁷ PFU/mL

	262 (CIP 104340)	1 x 10 ⁶ PFU/ml
	Slovakia 14-10 (29055)	1 x 10 ⁶ PFU/ml
Streptococcus pyogenes	Typing strain T1 (NCIG 11841, SF 130)	1 x 10 ⁶ PFU/ml
	Mutant 23	1 x 10 ⁶ PFU/ml
Mycoplasma pneumoniae	FH strain of Eaton Agent (NCIC 10119)	1 x 10 ⁶ PFU/ml
	36M129-67	1 x 10 ⁶ PFU/ml
	229E	1.5 x 10 ⁶ TCID ₅₀ /ml
Coronavirus	OC43	1.5 x 10 ⁶ TCID ₅₀ /ml
	NL63	1.5 x 10 ⁶ TCID ₅₀ /ml
	HKU1	1.5 x 10 ⁶ TCID ₅₀ /ml
Human rotavirus (HMPV) 3 Type B1	Peru-2002	1.5 x 10 ⁶ TCID ₅₀ /ml
Human Metapneumovirus (HMPV) 16 Type A1	IA10-2003	1.5 x 10 ⁶ TCID ₅₀ /ml
	Type 1	1.5 x 10 ⁶ TCID ₅₀ /ml
	Type 2	1.5 x 10 ⁶ TCID ₅₀ /ml
	Type 3	1.5 x 10 ⁶ TCID ₅₀ /ml
	Type 4A	1.5 x 10 ⁶ TCID ₅₀ /ml

Interfering Substances Reaction

When tested using the Novel Coronavirus (SARS-CoV-2) Antigen Rapid Test Device (saliva), there was no interference between the device reagents and the Potential interference substances listed in below table that would create false positive or negative results for SARS-CoV-2 antigen.

Substance	Concentration	Substance	Concentration
Mucin	100µg/mL	Acetylsalicylic acid	3.0 mM
Whole Blood	5% (v/v)	Ibuprofen	2.5 mM
Biotin	100µg/mL	Maprofen	10 mg/mL
Neo-Synephrine (Phenylephrine)	5% (w/v)	Tobramycin	10 µg/mL
Afrin Nasal Spray (Oxymetazoline)	5% (w/v)	Erythromycin	50µM
Saline Nasal Spray	5% (w/v)	Ciprofloxacin	50µM
Homeopathic	5% (w/v)	Ceftriaxone	110mg/mL
Sodium Cromoglycate	10 mg/mL	Meropenem	3.7 µg/mL
Doxylamine Hydrochloride	10 mg/mL	Tobramycin	100µg/mL
Zanamivir	5 mg/mL	Histamine Hydrochloride	100µg/mL
Oseltamivir	10 mg/mL	Peramivir	1mmol/mL
Artemether-lumefantrine	50µM	Flunisolide	100µg/mL
Doxycycline hyclate	50µM	Budesonide	0.64mmol/L
Quinine	150µM	Fluticasone	0.3µg/mL
Lamivudine	1 mg/mL	Losartan	5µg/mL
Ribavirin	1 mg/mL	Ritonavir	5 mg/mL
Dedecanovir	1 mg/mL	Abidol	117.8mg/mL
Acetaminophen	150µM	Pooled human nasal wash	N/A

Symbol	Meaning	Symbol	Meaning
	In vitro diagnostic medical device		Storage temperature limit
	Manufacturer		Authorized representative in the European Community
	Date of Manufacture		Use by date
	Do not reuse		Consult instruction for use
	Batch code		Meet the requirements of EC Directive 93/9/EC



HANGZHOU REALY TECH CO., LTD.
4th Floor, #12 Building, Eastern Medicine Town,
Xiaoshan Economic & Technology Development,
310018 Hangzhou, Zhejiang, P. R. China
Website: www.realytech.com



Luxus Lebenswelt GmbH
Kochstr. 1, 47877, Willich, Germany



Number 101431801
Version 1.5
Effective Date 2021-01-22



Annex II: Data of Clinical Tests

NO.	Age	Gender	Rapid Test	(RT-PCR)
1	49	F	Positive	Positive (RdRP and N gene)
2	32	F	Positive	Positive (RdRP and N gene)
3	31	F	Positive	Positive (RdRP and N gene)
4	32	F	Positive	Positive (RdRP and N gene)
5	21	F	Negative	Positive (RdRP gene)
6	51	M	Positive	Positive (RdRP and N gene)
7	22	F	Positive	Positive (RdRP and N gene)
8	46	F	Positive	Positive (RdRP and N gene)
9	23	F	Positive	Positive (RdRP and N gene)
10	14	M	positive	Positive (RdRP and N gene)
11	42	M	Positive	Positive (RdRP and N gene)
12	51	M	Positive	Positive (RdRP and N gene)
13	80	M	Positive	Positive (RdRP and N gene)
14	39	F	Negative	Positive (N gene)
15	67	M	Positive	Positive (RdRP and N gene)
16	44	M	positive	Positive (RdRP gene)
17	26	F	Positive	Positive (RdRP and N gene)
18	33	F	positive	Positive (N gene)
19	38	F	Positive	Positive (RdRP and N gene)
20	36	F	Positive	Positive (RdRP and N gene)
21	3	F	Positive	Positive (RdRP and N gene)
22	35	F	Positive	Positive (RdRP and N gene)
23	23	F	Positive	Positive (RdRP and N gene)

NO.	Age	Gender	Rapid Test	(RT-PCR)
24	43	M	Positive	Positive (RdRP and N gene)
25	43	F	Negative	Positive (N gene)
26	46	F	Positive	Positive (RdRP and N gene)
27	55	F	Positive	Positive (RdRP and N gene)
28	22	F	Positive	Positive (RdRP and N gene)
29	20	M	positive	Positive (N gene)
30	42	M	Positive	Positive (RdRP and N gene)
31	56	F	Positive	Positive (RdRP and N gene)
32	55	M	Positive	Positive (RdRP and N gene)
33	26	F	Positive	Positive (RdRP and N gene)
34	54	M	Positive	Positive (RdRP and N gene)
35	43	F	Positive	Positive (RdRP and N gene)
36	69	M	Positive	Positive (RdRP and N gene)
37	36	M	Negative	Positive (N gene)
38	37	F	Positive	Positive (RdRP and N gene)
39	44	F	Positive	Positive (RdRP and N gene)
40	43	F	Positive	Positive (RdRP and N gene)
41	67	F	Positive	Positive (RdRP and N gene)
42	51	F	Positive	Positive (RdRP and N gene)
43	75	F	Positive	Positive (RdRP and N gene)
44	60	F	Positive	Positive (RdRP and N gene)
45	25	M	Positive	Positive (RdRP and N gene)
46	75	F	Positive	Positive (RdRP and N gene)



NO.	Age	Gender	Rapid Test	(RT-PCR)
47	43	F	Positive	Positive (RdRP and N gene)
48	30	F	Positive	Positive (RdRP and N gene)
49	30	M	Negative	Positive (RdRP gene)
50	26	F	Positive	Positive (RdRP and N gene)
51	32	F	Positive	Positive (RdRP and N gene)
52	73	M	Positive	Positive (RdRP and N gene)
53	58	F	Positive	Positive (RdRP and N gene)
54	66	F	Positive	Positive (RdRP and N gene)
55	29	F	Positive	Positive (RdRP and N gene)
56	56	M	Positive	Positive (RdRP and N gene)
57	24	M	Positive	Positive (N gene)
58	36	M	Positive	Positive (RdRP and N gene)
59	70	F	Positive	Positive (RdRP and N gene)
60	45	M	Positive	Positive (RdRP and N gene)
61	38	F	Positive	Positive (RdRP and N gene)
62	42	M	Positive	Positive (RdRP and N gene)
63	55	M	Positive	Positive (RdRP and N gene)
64	33	M	Positive	Positive (RdRP and N gene)
65	39	M	Positive	Positive (RdRP and N gene)
66	58	F	Negative	Positive (N gene)
67	20	F	Positive	Positive (RdRP and N gene)
68	42	F	Positive	Positive (RdRP and N gene)
69	56	M	Positive	Positive (RdRP and N gene)
70	55	F	Positive	Positive (RdRP and N gene)

NO.	Age	Gender	Rapid Test	(RT-PCR)
71	26	F	Positive	Positive (RdRP and N gene)
72	54	M	Positive	Positive (RdRP and N gene)
73	45	F	Positive	Positive (RdRP and N gene)
74	38	M	Positive	Positive (RdRP and N gene)
75	42	M	Positive	Positive (RdRP and N gene)
76	55	F	Positive	Positive (RdRP and N gene)
77	33	F	Positive	Positive (RdRP and N gene)
78	43	F	Negative	Positive (N gene)
79	67	M	Positive	Positive (RdRP and N gene)
80	51	F	Positive	Positive (RdRP and N gene)
81	75	M	Positive	Positive (RdRP and N gene)
82	60	M	Positive	Positive (RdRP and N gene)
83	25	F	Positive	Positive (RdRP and N gene)
84	75	M	Positive	Positive (N gene)
85	43	F	Positive	Positive (RdRP and N gene)
86	49	F	Positive	Positive (RdRP and N gene)
87	32	F	Positive	Positive (RdRP and N gene)
88	31	M	Positive	Positive (RdRP and N gene)
89	32	M	Positive	Positive (RdRP and N gene)
90	21	M	Positive	Positive (RdRP and N gene)
91	51	F	Positive	Positive (RdRP and N gene)
92	22	M	Positive	Positive (RdRP and N gene)
93	46	F	Positive	Positive (RdRP and N gene)
94	23	M	Positive	Positive (RdRP and N gene)



NO.	Age	Gender	Rapid Test	(RT-PCR)
95	14	F	Positive	Positive (RdRP and N gene)
96	55	M	Negative	Positive (N gene)
97	33	M	Positive	Positive (RdRP and N gene)
98	43	F	Positive	Positive (RdRP and N gene)
99	67	M	Positive	Positive (RdRP and N gene)
100	51	M	Positive	Positive (RdRP and N gene)
101	75	M	Positive	Positive (N gene)
102	60	M	Positive	Positive (RdRP and N gene)
103	25	M	Positive	Positive (RdRP and N gene)
104	75	M	Positive	Positive (RdRP and N gene)
105	43	M	Positive	Positive (RdRP and N gene)
106	49	M	Positive	Positive (RdRP and N gene)
107	32	F	Positive	Positive (RdRP and N gene)
108	31	M	Positive	Positive (RdRP and N gene)
109	32	M	Positive	Positive (RdRP and N gene)
110	21	F	Positive	Positive (RdRP and N gene)
111	51	F	Positive	Positive (RdRP and N gene)
112	26	F	Positive	Positive (RdRP and N gene)
113	33	M	Positive	Positive (RdRP and N gene)
114	38	F	Positive	Positive (RdRP and N gene)
115	36	M	Positive	Positive (RdRP and N gene)
116	3	M	Positive	Positive (RdRP and N gene)
117	35	F	Positive	Positive (RdRP and N gene)
118	23	M	Positive	Positive (RdRP and N gene)

NO.	Age	Gender	Rapid Test	(RT-PCR)
119	43	F	Positive	Positive (RdRP and N gene)
120	75	F	Positive	Positive (RdRP and N gene)
121	60	M	Positive	Positive (RdRP and N gene)
122	25	M	Positive	Positive (N gene)
123	75	F	Positive	Positive (RdRP and N gene)
124	43	F	Positive	Positive (RdRP and N gene)
125	49	F	Negative	Positive (N gene)
126	32	F	Positive	Positive (RdRP and N gene)
127	31	F	Positive	Positive (RdRP and N gene)
128	32	F	Positive	Positive (RdRP and N gene)
129	21	F	Positive	Positive (RdRP and N gene)
130	51	F	Positive	Positive (RdRP and N gene)
131	26	F	Positive	Positive (RdRP and N gene)
132	33	M	Positive	Positive (RdRP and N gene)
133	38	M	Positive	Positive (RdRP and N gene)
134	36	F	Negative	Positive (RdRP gene)
135	3	M	Positive	Positive (RdRP and N gene)
136	75	M	Positive	Positive (RdRP and N gene)
137	43	M	Positive	Positive (RdRP and N gene)
138	49	M	Positive	Positive (RdRP and N gene)
139	32	M	Positive	Positive (N gene)
140	31	M	Positive	Positive (RdRP and N gene)
141	32	M	Positive	Positive (RdRP and N gene)
142	21	M	Positive	Positive (RdRP and N gene)



NO.	Age	Gender	Rapid Test	(RT-PCR)
143	51	M	Positive	Positive (RdRP and N gene)
144	22	M	Negative	Positive (N gene)
145	46	F	Positive	Positive (RdRP and N gene)
146	23	M	Positive	Positive (RdRP and N gene)
147	14	M	Positive	Positive (RdRP and N gene)
148	55	F	Positive	Positive (RdRP and N gene)
149	33	M	Positive	Positive (RdRP and N gene)
150	26	F	Positive	Positive (RdRP and N gene)
151	32	M	Positive	Positive (RdRP and N gene)
152	73	M	Positive	Positive (RdRP and N gene)
153	58	M	Positive	Positive (RdRP and N gene)
154	66	M	Positive	Positive (RdRP and N gene)
155	29	M	Positive	Positive (RdRP and N gene)
156	56	F	Positive	Positive (N gene)
157	24	F	Positive	Positive (RdRP and N gene)
158	36	F	Positive	Positive (RdRP and N gene)
159	70	M	Positive	Positive (RdRP and N gene)
160	45	F	Positive	Positive (RdRP and N gene)
161	74	M	Positive	Positive (RdRP and N gene)
162	43	M	Positive	Positive (RdRP and N gene)
163	68	M	Negative	Positive (N gene)
164	29	F	Positive	Positive (RdRP and N gene)
165	54	F	Positive	Positive (RdRP and N gene)
166	49	F	Positive	Positive (RdRP and N gene)

NO.	Age	Gender	Rapid Test	(RT-PCR)
167	20	M	Positive	Positive (RdRP and N gene)
168	26	F	Positive	Positive (N gene)
169	22	F	Positive	Positive (RdRP and N gene)
170	32	M	Negative	Negative(Ct/Cq) >40
171	28	F	Negative	Negative(Ct/Cq) >40
172	44	M	Negative	Negative(Ct/Cq) >40
173	18	F	Negative	Negative(Ct/Cq) >40
174	71	F	Negative	Negative(Ct/Cq) >40
175	37	M	Negative	Negative(Ct/Cq) >40
176	44	M	Negative	Negative(Ct/Cq) >40
177	79	F	Negative	Negative(Ct/Cq) >40
178	67	M	Negative	Negative(Ct/Cq) >40
179	61	F	Negative	Negative(Ct/Cq) >40
180	59	F	Negative	Negative(Ct/Cq) >40
181	28	F	Negative	Negative(Ct/Cq) >40
182	82	M	Negative	Negative(Ct/Cq) >40
183	63	F	Negative	Negative(Ct/Cq) >40
184	53	M	Negative	Negative(Ct/Cq) >40
185	43	M	Negative	Negative(Ct/Cq) >40
186	46	M	Negative	Negative(Ct/Cq) >40
187	46	F	Negative	Negative(Ct/Cq) >40
188	21	F	Negative	Negative(Ct/Cq) >40
189	46	F	Negative	Negative(Ct/Cq) >40
190	71	M	Negative	Negative(Ct/Cq) >40



NO.	Age	Gender	Rapid Test	(RT-PCR)
191	60	F	Negative	Negative(Ct/Cq) >40
192	31	F	Negative	Negative(Ct/Cq) >40
193	72	M	Negative	Negative(Ct/Cq) >40
194	62	M	Negative	Negative(Ct/Cq) >40
195	39	F	Negative	Negative(Ct/Cq) >40
196	45	M	Negative	Negative(Ct/Cq) >40
197	21	M	Negative	Negative(Ct/Cq) >40
198	33	M	Negative	Negative(Ct/Cq) >40
199	83	M	Negative	Negative(Ct/Cq) >40
200	15	M	Negative	Negative(Ct/Cq) >40
201	59	M	Negative	Negative(Ct/Cq) >40
202	54	M	Negative	Negative(Ct/Cq) >40
203	84	F	Negative	Negative(Ct/Cq) >40
204	84	F	Negative	Negative(Ct/Cq) >40
205	42	F	Negative	Negative(Ct/Cq) >40
206	63	F	Negative	Negative(Ct/Cq) >40
207	29	M	Negative	Negative(Ct/Cq) >40
208	50	M	Negative	Negative(Ct/Cq) >40
209	74	F	Negative	Negative(Ct/Cq) >40
210	43	M	Negative	Negative(Ct/Cq) >40
211	68	M	Negative	Negative(Ct/Cq) >40
212	29	M	Negative	Negative(Ct/Cq) >40
213	54	M	Negative	Negative(Ct/Cq) >40
214	49	M	Negative	Negative(Ct/Cq) >40

NO.	Age	Gender	Rapid Test	(RT-PCR)
215	20	M	Negative	Negative(Ct/Cq) >40
216	26	M	Negative	Negative(Ct/Cq) >40
217	22	M	Negative	Negative(Ct/Cq) >40
218	32	F	Negative	Negative(Ct/Cq) >40
219	28	M	Negative	Negative(Ct/Cq) >40
220	44	M	Negative	Negative(Ct/Cq) >40
221	57	F	Negative	Negative(Ct/Cq) >40
222	64	F	Negative	Negative(Ct/Cq) >40
223	39	F	Negative	Negative(Ct/Cq) >40
224	38	F	Negative	Negative(Ct/Cq) >40
225	73	M	Negative	Negative(Ct/Cq) >40
226	45	M	Negative	Negative(Ct/Cq) >40
227	61	M	Negative	Negative(Ct/Cq) >40
228	13	F	Negative	Negative(Ct/Cq) >40
229	64	F	Negative	Negative(Ct/Cq) >40
230	26	F	Negative	Negative(Ct/Cq) >40
231	28	M	Negative	Negative(Ct/Cq) >40
232	58	M	Negative	Negative(Ct/Cq) >40
233	35	F	Negative	Negative(Ct/Cq) >40
234	51	M	Negative	Negative(Ct/Cq) >40
235	60	M	Negative	Negative(Ct/Cq) >40
236	17	M	Negative	Negative(Ct/Cq) >40
237	18	F	Negative	Negative(Ct/Cq) >40
238	15	M	Negative	Negative(Ct/Cq) >40



NO.	Age	Gender	Rapid Test	(RT-PCR)
263	52	M	Negative	Negative(Ct/Cq) >40
264	70	M	Negative	Negative(Ct/Cq) >40
265	63	M	Negative	Negative(Ct/Cq) >40
266	59	M	Negative	Negative(Ct/Cq) >40
267	26	M	Negative	Negative(Ct/Cq) >40
268	36	F	Negative	Negative(Ct/Cq) >40
269	47	F	Negative	Negative(Ct/Cq) >40
270	45	M	Negative	Negative(Ct/Cq) >40
271	29	F	Negative	Negative(Ct/Cq) >40
272	30	M	Negative	Negative(Ct/Cq) >40
273	25	F	Negative	Negative(Ct/Cq) >40
274	73	M	Negative	Negative(Ct/Cq) >40
275	76	M	Negative	Negative(Ct/Cq) >40
276	25	M	Negative	Negative(Ct/Cq) >40
277	49	F	Negative	Negative(Ct/Cq) >40
278	62	M	Negative	Negative(Ct/Cq) >40
279	38	M	Negative	Negative(Ct/Cq) >40
280	33	M	Negative	Negative(Ct/Cq) >40
281	39	M	Negative	Negative(Ct/Cq) >40
282	69	M	Negative	Negative(Ct/Cq) >40
283	79	F	Negative	Negative(Ct/Cq) >40
284	32	M	Positive	Negative(Ct/Cq) >40
285	35	M	Negative	Negative(Ct/Cq) >40
286	39	M	Negative	Negative(Ct/Cq) >40



NO.	Age	Gender	Rapid Test	(RT-PCR)
287	61	F	Negative	Negative(Ct/Cq) >40
288	10	F	Negative	Negative(Ct/Cq) >40
289	37	M	Negative	Negative(Ct/Cq) >40
290	52	F	Negative	Negative(Ct/Cq) >40
291	41	M	Negative	Negative(Ct/Cq) >40
292	74	M	Negative	Negative(Ct/Cq) >40
293	51	F	Negative	Negative(Ct/Cq) >40
294	56	M	Negative	Negative(Ct/Cq) >40
295	62	F	Negative	Negative(Ct/Cq) >40
296	60	F	Negative	Negative(Ct/Cq) >40
297	54	F	Negative	Negative(Ct/Cq) >40
298	81	F	Negative	Negative(Ct/Cq) >40
299	79	F	Negative	Negative(Ct/Cq) >40
300	73	F	Negative	Negative(Ct/Cq) >40
301	35	F	Negative	Negative(Ct/Cq) >40
302	76	F	Negative	Negative(Ct/Cq) >40
303	23	M	Negative	Negative(Ct/Cq) >40
304	13	F	Negative	Negative(Ct/Cq) >40
305	14	M	Negative	Negative(Ct/Cq) >40
306	43	M	Negative	Negative(Ct/Cq) >40
307	30	F	Negative	Negative(Ct/Cq) >40
308	57	M	Negative	Negative(Ct/Cq) >40
309	30	F	Negative	Negative(Ct/Cq) >40
310	65	M	Negative	Negative(Ct/Cq) >40

NO.	Age	Gender	Rapid Test	(RT-PCR)
311	66	F	Negative	Negative(Ct/Cq) >40
312	38	F	Negative	Negative(Ct/Cq) >40
313	49	M	Negative	Negative(Ct/Cq) >40
314	23	F	Negative	Negative(Ct/Cq) >40
315	51	M	Negative	Negative(Ct/Cq) >40
316	64	F	Negative	Negative(Ct/Cq) >40
317	67	M	Negative	Negative(Ct/Cq) >40
318	34	M	Negative	Negative(Ct/Cq) >40
319	55	M	Negative	Negative(Ct/Cq) >40
320	58	M	Negative	Negative(Ct/Cq) >40
321	67	F	Negative	Negative(Ct/Cq) >40
322	20	F	Negative	Negative(Ct/Cq) >40
323	42	M	Negative	Negative(Ct/Cq) >40
324	59	M	Negative	Negative(Ct/Cq) >40
325	12	M	Negative	Negative(Ct/Cq) >40
326	30	M	Negative	Negative(Ct/Cq) >40
327	65	M	Negative	Negative(Ct/Cq) >40
328	66	F	Negative	Negative(Ct/Cq) >40
329	38	F	Negative	Negative(Ct/Cq) >40
330	49	M	Negative	Negative(Ct/Cq) >40
331	23	F	Negative	Negative(Ct/Cq) >40
332	51	M	Negative	Negative(Ct/Cq) >40
333	64	M	Negative	Negative(Ct/Cq) >40
334	67	F	Negative	Negative(Ct/Cq) >40



NO.	Age	Gender	Rapid Test	(RT-PCR)
335	34	M	Negative	Negative(Ct/Cq) >40
336	55	F	Negative	Negative(Ct/Cq) >40
337	58	F	Negative	Negative(Ct/Cq) >40
338	67	F	Negative	Negative(Ct/Cq) >40
339	20	F	Negative	Negative(Ct/Cq) >40
340	42	F	Negative	Negative(Ct/Cq) >40
341	59	F	Negative	Negative(Ct/Cq) >40
342	12	F	Negative	Negative(Ct/Cq) >40
343	23	F	Negative	Negative(Ct/Cq) >40
344	51	M	Negative	Negative(Ct/Cq) >40
345	64	F	Negative	Negative(Ct/Cq) >40
346	67	M	Negative	Negative(Ct/Cq) >40
347	34	M	Negative	Negative(Ct/Cq) >40
348	55	F	Negative	Negative(Ct/Cq) >40
349	58	M	Negative	Negative(Ct/Cq) >40
350	67	F	Negative	Negative(Ct/Cq) >40
351	20	M	Negative	Negative(Ct/Cq) >40
352	42	F	Negative	Negative(Ct/Cq) >40
353	59	F	Negative	Negative(Ct/Cq) >40
354	12	M	Negative	Negative(Ct/Cq) >40
355	30	F	Negative	Negative(Ct/Cq) >40
356	65	M	Negative	Negative(Ct/Cq) >40
357	66	F	Negative	Negative(Ct/Cq) >40
358	38	M	Negative	Negative(Ct/Cq) >40

NO.	Age	Gender	Rapid Test	(RT-PCR)
359	49	F	Negative	Negative(Ct/Cq) >40
360	23	M	Negative	Negative(Ct/Cq) >40
361	51	F	Negative	Negative(Ct/Cq) >40
362	64	M	Negative	Negative(Ct/Cq) >40
363	67	M	Negative	Negative(Ct/Cq) >40
364	34	F	Negative	Negative(Ct/Cq) >40
365	51	M	Negative	Negative(Ct/Cq) >40
366	64	F	Negative	Negative(Ct/Cq) >40
367	67	F	Negative	Negative(Ct/Cq) >40
368	34	F	Negative	Negative(Ct/Cq) >40
369	55	F	Negative	Negative(Ct/Cq) >40
370	58	F	Negative	Negative(Ct/Cq) >40
371	67	F	Negative	Negative(Ct/Cq) >40
372	20	F	Negative	Negative(Ct/Cq) >40
373	42	F	Negative	Negative(Ct/Cq) >40
374	59	M	Negative	Negative(Ct/Cq) >40
375	12	M	Negative	Negative(Ct/Cq) >40
376	23	F	Negative	Negative(Ct/Cq) >40
377	51	F	Negative	Negative(Ct/Cq) >40
378	64	M	Negative	Negative(Ct/Cq) >40
379	67	M	Negative	Negative(Ct/Cq) >40
380	34	M	Negative	Negative(Ct/Cq) >40
381	55	F	Negative	Negative(Ct/Cq) >40
382	58	M	Negative	Negative(Ct/Cq) >40



NO.	Age	Gender	Rapid Test	(RT-PCR)
383	67	M	Negative	Negative(Ct/Cq) >40
384	20	F	Negative	Negative(Ct/Cq) >40
385	42	M	Negative	Negative(Ct/Cq) >40
386	59	F	Negative	Negative(Ct/Cq) >40
387	12	M	Negative	Negative(Ct/Cq) >40
388	30	M	Negative	Negative(Ct/Cq) >40
389	65	M	Negative	Negative(Ct/Cq) >40
390	66	M	Negative	Negative(Ct/Cq) >40
391	38	M	Negative	Negative(Ct/Cq) >40
392	49	F	Negative	Negative(Ct/Cq) >40
393	23	F	Negative	Negative(Ct/Cq) >40
394	67	F	Negative	Negative(Ct/Cq) >40

Director: 

Date: 2021.01.23

Seal of company signature



NO.	Age	Gender	Rapid Test	(RT-PCR)
395	20	F	Negative	Negative(Ct/Cq) >40
396	42	F	Negative	Negative(Ct/Cq) >40
397	59	F	Negative	Negative(Ct/Cq) >40
398	12	F	Negative	Negative(Ct/Cq) >40
399	30	F	Negative	Negative(Ct/Cq) >40
400	65	M	Negative	Negative(Ct/Cq) >40
401	66	M	Negative	Negative(Ct/Cq) >40
402	30	F	Negative	Negative(Ct/Cq) >40
403	65	F	Negative	Negative(Ct/Cq) >40
404	66	M	Negative	Negative(Ct/Cq) >40
405	67	M	Negative	Negative(Ct/Cq) >40